Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-B-FAHF-2 in Mild-To-Moderate Crohn's Disease
NCT03992469Phase 1Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Feb 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Crohn's disease comparing E-B-FAHF-2 with Placebo (2 arms). Primary endpoint: Number of grades of adverse events at 8 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
E-B-FAHF-2
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03992469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992469.